Eosinophilic Esophagitis (EoE) Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis
The Primary objective is to demonstrate the efficacy of dupilumab treatment compared with placebo in pediatric patients with active eosinophilic esophagitis (EoE) based on histologic improvement meeting validated histologic criteria. The Secondary objectives are: - To demonstrate the efficacy of dupilumab compared to placebo in pediatric patients with active EoE after 16 weeks of treatment as assessed by endoscopic visual measurements of disease activity using the Eosinophilic Esophagitis-Endoscopic Reference Score (EoE-EREFS) and histologic abnormalities as measured by the EoE Histology Scoring System (EoE-HSS) - To evaluate the safety, tolerability, and immunogenicity of dupilumab treatment for up to 16 weeks in pediatric patients with active EoE - To evaluate the effects of dupilumab on transcriptomic signatures associated with EoE and type 2 inflammation - To study the effects of dupilumab on the type 2 inflammation gene expression signature - To evaluate the concentration-time profile of functional dupilumab in serum in this population - To assess efficacy of long-term (up to 160 weeks) dupilumab treatment - To assess the impact of dupilumab treatment on changes in weight and growth during the extended active period and open-label extension period of the study - To assess safety, tolerability, and immunogenicity of long-term (up to 160 weeks) dupilumab treatment - To evaluate the impact of dupilumab treatment on EoE signs and symptoms
This is a 3-part study: - Part A: Double-blind 16-week treatment period - Part B: 36-week extended active treatment period - Part C: Up to108 weeks open-label extension period ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03245840 -
Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)
|
Phase 3 | |
| Completed |
NCT03581838 -
Eating With Eosinophilic Esophagitis (EoE)
|
||
| Completed |
NCT02778867 -
SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study
|
Phase 2/Phase 3 | |
| Completed |
NCT01642212 -
OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension
|
Phase 2 | |
| Completed |
NCT05485779 -
SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04626609 -
Prostaglandin and Cannabinoid Receptors in EoE
|
||
| Completed |
NCT00762073 -
Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis
|
Phase 2 | |
| Terminated |
NCT02058537 -
Bethanechol for Eosinophilic Esophagitis
|
Phase 2 | |
| Completed |
NCT02605837 -
A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved
|
Phase 3 | |
| Completed |
NCT02320981 -
Mucosal Impedance in Pediatric Population
|
N/A | |
| Recruiting |
NCT06389994 -
Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy
|
||
| Completed |
NCT02736409 -
An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)
|
Phase 3 |